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Reply to the Editor:
Wewould like to thankDrs Asano and Okita
for their comments regarding our study,1 in
which we demonstrated that the majority of
arch aneurysms could be repaired with
a long elephant trunk (LET) anastomosed
at the base of the innominate artery without
distal anastomosis in the descending aorta.
They raised the issue of distal fixation of
the LET in our technique. Although the
proximal end of the LET is sutured at the
base of the innominate artery and proximal
endoleak is prevented, the distal end of the
LET is not fixed, and distal endoleak is pos-
sible with our method. As demonstrated in
Figure 2, C, in our article, the aneurysmal
sac outside the LET was enhanced with con-
trast material in 9% of our patients, and they
required distal fixation of the LET.
However, it is important to note that the
majority (91%) of our patients did not
show contrast material outside the LET,
and none had expansion or rupture of the an-
eurysm occur during the average follow-up
of 336 18 months. Furthermore, it was en-
couraging for us to find that the nonen-
hanced aneurysmal sac around the LET
shrank more than 5 mm in 82% of the pa-
tients and more than 10 mm in 50% at 1
year after total arch replacement with the
LET, as shown in Figure 2, B, of our article.
The follow-up period might not have been
long enough to rule out the possibility of
late expansion of a nonenhanced aneurysm,
and we consider that long-term follow-up of
our patients is mandatory.
In their letter they referred to their arti-
cle,2 in which they insist that arch aneu-
rysms with extension to 1 cm below the
level of the carina are accessible from a me-
dian sternotomy. Interestingly, they demon-
strate that an increased depth of distal
anastomosis is a risk factor for prolonged
distal anastomosis, even in Japanese pa-
tients, whose chest cavities are generally
smaller than those in white patients.2 Based
on my personal experience as a clinical
fellow for 3 years in United States, I wonder
how many surgeons are comfortable to do
the distal anastomosis 1 cm below the level
of the carina in a typical barrel-chested
white patient. On the other hand, with our
technique, the descending aorta in the deep
posterior mediastinum does not need to be
exposed, but rather only a distal anastomo-
sis is performed in the distal ascending
aorta. Because of this simplicity, we re-
quired only 236 8 minutes of hypothermic
circulatory arrest in the lower body to com-
plete the insertion and anastomoses of the
LET. Thus we conceive that the benefit of
our technique might be even more evident
in white patients with a large chest.
Koichi Toda, MD
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Letters to the EditorTissue-engineered heart valves:
Bioreactor—yes or no?
To the Editor:
I read with great interest the article by Vin-
centelli and associates.1 In this article the au-
thors present the results of the effects of in
situ injection of autologous bone marrow–
derived mononuclear cells and mesenchy-
mal stem cells (MSCs) on the outcome
of xenogenic decellularized scaffolds in
a lamb model. The main focus of this article
is on a new method to reseed the cells in
valve scaffolds consisting of an in situ injec-
tion of bone marrow cells into a porcine
decellularized scaffold before implantation.
Tissue-engineered heart valves created
from MSCs and injected directly in a decel-
lularized xenograft scaffold exhibited
satisfactory hemodynamic aspects after 4
months.
Even if the authors demonstrate that in
the MSC group the global organization of
collagen fibers was preserved, a few fusi-The Journal of Thoracic and Cardiovasculaform cells were observed in the subendothe-
lial area and the adventitia.
Pulmonary leaflets present few recolo-
nizing cells positive for a-actin staining,
with a typical organization in 3 layers,
fibrosa, spongiosa, and ventricularis, as pre-
viously reported by others,2 who showed
that decellularized pulmonary valves re-
vealed a well-preserved 3-dimensional net-
work of collagen fibers in the extracellular
matrix.
As we know, maintenance of the struc-
tural valve properties is fundamental to pre-
serve the extracellular matrix with its
complex of glycosaminoglycans and colla-
gen fibers produced from valve fibroblasts
and active fibroblasts. This appears to be
fundamental for the mechanical valve’s
capability and its long-term durability.2-4
Repopulation of a decellularized valve is
crucial for valve vitality. How this could
be achieved still remains controversial. As
a matter of fact, at this time, it is not
completely clear whether a bioreactor is
fundamental for the valve repopulation.
Lichtenberg and colleagues5 clearly demon-
strated that in vitro conditioning of engi-
neered tissues in a bioreactive system
stimulates and enhances the production of
extracellular matrix and the related tissue
strength. On the contrary, Dohmen and
associates,6 studying seeded or nonseeded
decellularized valves implanted into right
ventricular juvenile sheep outflow tracts,
showed that a difference was identified in
the recellularization density of in vitro
seeded and nonseeded valves up to 3
months, but no such difference was seen
after 6 months.
Nevertheless, a moderate pulsatile flow
with small increments seems to be able to
stimulate endothelial cell proliferation on
the decellularized valve scaffold. A rapid
increase in bioreactor flow to physiologic
levels leads to significant damage of the
reseeded endothelium and complete loss of
cusp cellularity. This effect might be
responsible for the in vivo failure of static,
reseeded, tissue-engineered valves exposed
to physiologic hemodynamic forces.
However, whether MSCs injected in the
scaffold induced in situ differentiation into
myofibroblasts and endothelial cells re-
mains uncertain. The injection of the stem
cells in the inner side of the valve before
valve implantation must be able to produce
a colonization not only by recipient
endothelial cells but above all by activer Surgery c Volume 135, Number 5 1189
Reply to the Editor:
We thank Dr Dainese for this comment.
Several groups have demonstrated that in
vitro seeding of cells on artificial scaffolds
or on natural matrices in a biomimetic envi-
ronment succeeded in the generation of
functional tissue-engineered heart valves.1,2
More recently, Yacoub3 has said in an inter-
view about mesenchymal stem cells that ‘‘if
you subject these cells, in a 3 dimensional
matrix, to programmes of conditioning us-
ing cyclic pressure of a predefined nature,
they change their phenotype to one that is
very similar to valve tissue.’’ Yacoub and
his team still believe that the future of the
tissue-engineered heart valve is dependant
of an in vitro seeding in a bioreactor. To
our knowledge, for the first time in this
field, our work4 suggests that direct injec-
tion of mesenchymal stem cells seems to
induce almost physiologic recolonization
of valvular matrix under physiologic shear
stress. Re-endothelialization of a decellular-
ized xenogeneic matrix can be obtained
in vivo without the cumbersome step of
bioreactor recellularization. This has the ev-
ident advantage of simplifying the recellula-
rization procedure and guaranteeing that
recolonizing cells will stand the actual
high shear conditions of a cardiac valve.
However, we have to underline the evident
limits of our work. First, we do not know
at the present time whether the recolonizing
cells directly derive from the injected cells
or from autologous cells migrating from
blood or neighboring tissue. Second, as sug-
gested by Dainese et al, a longer follow-up
period is mandatory and should be pro-
longed for more than 1 year to confirm our
results.
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Letters to the Editorfibroblasts. These should be able to continu-
ally remodel the valve matrix and produce
its components (eg, glycosaminoglycans)
with very high turnover.
On this basis, this work is a great con-
tribution in the complex field of engineered
tissue valves, and the announcement is
impressive because it should be able to
offer a different and easier way to reseed
valves before implantation. The authors are
congratulated for their current achievements
and should be encouraged to validate their
results in other in vivo models.
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